Weber B, Hopwood J J, Yogalingam G
Lysosomal Diseases Research Unit, Department of Chemical Pathology, Women's and Children's Hospital, 72 King William Road, SA 5006, North Adelaide, Australia.
Protein Expr Purif. 2001 Mar;21(2):251-9. doi: 10.1006/prep.2000.1361.
Mucopolysaccharidosis type IIIB (MPS-IIIB, Sanfilippo type B Syndrome) is a heterosomal, recessive lysosomal storage disorder resulting from a deficiency of [alpha]-N-acetylglucosaminidase (NAGLU). To characterize this enzyme further and evaluate its potential for enzyme replacement studies we expressed the NAGLU-encoding cDNA in Chinese hamster ovary cells (CHO-K1 cells) and purified the recombinant enzyme from the medium of stably transfected cells by a two-step affinity chromatography. Two isoforms of recombinant NAGLU with apparent molecular weights of 89 and 79 kDa were purified and shown to differ in their glycosylation pattern. The catalytic parameters of both forms of the recombinant enzyme were indistinguishable from each other and similar to those of NAGLU purified from various tissues. However, compared to other recombinant lysosomal enzymes expressed from CHO-K1 cells, the mannose-6-phosphate receptor mediated uptake of the secreted form of recombinant NAGLU into cultured skin fibroblasts was considerably reduced. A small amount of phosphorylated NAGLU present in purified enzyme preparations was shown to be endocytosed by MPS-IIIB fibroblasts via the mannose-6-phosphate receptor-mediated pathway and transported to the lysosomes, where they corrected the storage phenotype. Direct metabolic labeling experiments with Na(2) (32)PO(4) confirmed that the specific phosphorylation of recombinant NAGLU secreted from transfected CHO cells is significantly lower when compared with a control lysosomal enzyme. These results suggest that the use of secreted NAGLU in future enzyme and gene replacement therapy protocols will be severely limited due to its small degree of mannose-6-phosphorylation.
IIIB型粘多糖贮积症(MPS-IIIB,Sanfilippo B综合征)是一种常染色体隐性溶酶体贮积病,由α-N-乙酰氨基葡萄糖苷酶(NAGLU)缺乏引起。为了进一步表征这种酶并评估其在酶替代研究中的潜力,我们在中国仓鼠卵巢细胞(CHO-K1细胞)中表达了编码NAGLU的cDNA,并通过两步亲和色谱法从稳定转染细胞的培养基中纯化了重组酶。纯化出了两种重组NAGLU同工型,其表观分子量分别为89 kDa和79 kDa,且糖基化模式不同。两种形式的重组酶的催化参数彼此无差异,且与从各种组织中纯化的NAGLU相似。然而,与从CHO-K1细胞表达的其他重组溶酶体酶相比,甘露糖-6-磷酸受体介导的重组NAGLU分泌形式被摄取到培养的皮肤成纤维细胞中的能力大大降低。纯化酶制剂中存在的少量磷酸化NAGLU被证明可通过甘露糖-6-磷酸受体介导的途径被MPS-IIIB成纤维细胞内吞并转运至溶酶体,在那里它们纠正了贮积表型。用Na(2) (32)PO(4)进行的直接代谢标记实验证实,与对照溶酶体酶相比,转染的CHO细胞分泌的重组NAGLU的特异性磷酸化显著降低。这些结果表明,由于其甘露糖-6-磷酸化程度较低,未来在酶和基因替代治疗方案中使用分泌型NAGLU将受到严重限制。